American Society of Clinical Oncology clinical practice guideline update on the Use of chemotherapy sensitivity and resistance assays

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3328-3330

  Burstein, Harold J ^a   Mangu, Pamela B ^b   Somerfield, Mark R ^b   Schrag, Deborah ^a   Samson, David ^c   Holt, Lawrence ^d   Zelman, Debra ^e   Ajani, Jaffer A ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c Blue Cross and Blue Shield Association   (United States)

^d Coastal Cancer Center ^*  (United States)

^e Debbie's Dream Foundation   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; METHYL THIAZOLYL DIPHENYL TETRAZOLIUM BROMIDE; UNCLASSIFIED DRUG;

ASSAY; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY SENSITIVITY AND RESISTANCE ASSAY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL PRACTICE; META ANALYSIS (TOPIC); NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 80052001030     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.0354     Document Type: Short Survey

References (7)

1. Schrag D., Garewal H.S., Burstein H.J., et al:American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 22:3631-3638, 2004 (Pubitemid 41103670)
2. Cree I.A., Kurbacher C.M., Lamont A., et al: A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:1093-1101, 2007 (Pubitemid 47294903)
3. Ugurel S., Schadendorf D., Pfohler C., et al: In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 12:5454-5463, 2006 (Pubitemid 44497261)
4. Joo W.D., Lee J.Y., Kim J.H., et al: Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol 20:96-100, 2009
5. Wu B., Zhu J.S., Zhang Y., et al: Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution's experience. World J Gastroenterol 14:3064-3068, 2008
6. Gallion H., Christopherson W.A., Coleman R.L., et al: Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16:194-201, 2006
7. Mi Z., Holmes F.A., Hellerstedt B., et al: Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 28:1733-1740, 2008 (Pubitemid 351892877)